Remove 2025 Remove Clinical Trials Remove Conditions Remove Research and Development
article thumbnail

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. About MyMD Pharmaceuticals, Inc.

article thumbnail

Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

Cannabis Law Report

a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization (CRO) order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-? About MYMD-1.

article thumbnail

Second Edition Pharmaceutical Cannabis Report 2021: Featuring Almirall, Bayer and Novartis Among Others – ResearchAndMarkets.com

Cannabis Law Report

Research on the endocannabinoid system is one of the most promising avenues for new therapeutics in medicine at the moment. billion by 2025. The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space.

article thumbnail

A Hidden Origin Story of the CBD Craze

SMPL

For years, he’d been determined to connect the nascent CBD research he heard about at symposiums abroad with the medical marijuana movement in California. CBD industry will be worth $16 billion by 2025. This makes further research very difficult to do, and causes sick people in many states to be treated as criminals.

CBD 40
article thumbnail

Medical Cannabis Company Sunshine Coast Tikun Oceana, formerly known as Medifarm Calls In The Administrators

Cannabis Law Report

Last week, federal Health Minister Greg Hunt announced changes to regulations that would allow for medicinal cannabis exports, capitalising on what the Government estimated would be a $70 billion industry by 2025. Different strains for different conditions. Different strains are grown to treat different medical conditions.

article thumbnail

A New Treatment: CBD Oil For Autism?

Puff Puff Post

Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. They aren’t geared towards treating the condition specifically, and rather focus on reducing side-effects from the disorder like anxiety and insomnia. CBD Oil For Autism: How Can Cannabis Help?